COMMUNIQUÉS West-GlobeNewswire
-
Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer
01/07/2026 -
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
01/07/2026 -
ORYZON Raises €12 Million and Signs a Financing Agreement with COFIDES to Strengthen its Balance Sheet and Accelerate its Clinical Programs
01/07/2026 -
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
01/07/2026 -
Correction: Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026 -
LiveWorld Names Rob Thomas Vice President, Creative Director to Support Growing Healthcare Creative Practice
01/07/2026 -
JenaValve Recaps Key Highlights Including Late-Breaking Clinical Data from New York Valves 2026
01/07/2026 -
Creative Medical Technology Holdings Issues Mid-Year Update
01/07/2026 -
Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
01/07/2026 -
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
01/07/2026 -
Medline to report second quarter 2026 results on August 5, 2026
01/07/2026 -
Amoéba has received marketing authorization in France for its biofungicide AXPERA
01/07/2026 -
Amoéba obtient l’autorisation de mise sur le marché en France pour son biofongicide AXPERA
01/07/2026 -
Abivax announces trading resumption of its ordinary shares on Euronext Paris
01/07/2026 -
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
01/07/2026 -
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
01/07/2026 -
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma
01/07/2026 -
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
01/07/2026 -
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
01/07/2026
Pages